START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Siedner, Mark J. 2016. “START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection.” Open Forum Infectious Diseases 3 (1): ofw032. doi:10.1093/ofid/ofw032. http://dx.doi.org/10.1093/ofid/ofw032. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1093/ofid/ofw032                                                                                                                                                                           |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:26318544                                                                                                                                              |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection

Mark J. Siedner

Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston

The Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection (START) study has reinforced the benefits of early initiation of antiretroviral therapy (ART). However, a notable secondary finding from that study was that immediate initiation of ART did not prevent cardiovascular disease (CVD) events (0.17 vs 0.20 events/1000 person-years, \( P = .65 \)). This result appears to contradict a body of evidence, most notably from the Strategies for Management of Antiretroviral Therapy (SMART) study, which reported a 70% increased hazard of cardiovascular events for those deferring or interrupting treatment. Thus, an important unresolved question is whether the timing of ART impacts CVD risk. In this review, published data on relationships between timing of ART and CVD risk are reviewed. The data support a role for ART in mitigating CVD risk at lower CD4 counts, but data also suggests that, among those initiating therapy early, ART alone appears to suboptimally mitigate CVD risk. Additional interventions to address CVD risk among human immunodeficiency virus-infected populations are likely to be needed.

**Keywords.** antiretroviral therapy; cardiovascular disease; epidemiology; HIV/AIDS; systematic review.

Two recent landmark studies have lent strong support to a health benefit of early initiation of antiretroviral therapy (ART) for asymptomatic human immunodeficiency virus (HIV)-infected patients with high CD4 counts. Both the Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa (TEMPRANO) and the Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection (START) studies reported reductions of over 40% in the risk of death or an acquired immune deficiency syndrome (AIDS)-defining event when ART was initiated immediately instead of waiting until CD4 thresholds were met (<350 cells/µL in the START study, or the contemporary World Health Organization-based guidelines in the TEMPRANO study) [1,2]. Both studies demonstrated decreased risk of opportunistic infections and appreciable, albeit nonsignificant, reductions in all-cause mortality. However, an unexpected result from the START study was the rate of cardiovascular disease (CVD) events, which did not differ between immediate initiators and those deferring therapy (adjusted hazard ratio, 0.84; 95% confidence interval [CI], 0.39–1.81; \( P = .65 \)). The TEMPRANO study, which was not designed to capture cardiovascular events, did not report a similar subanalysis.

The finding that early ART for asymptomatic HIV-infected individuals did not prevent CVD complications seems to contradict a body of evidence relating HIV infection to CVD risk. Most notably, a landmark study comparing CD4-count-guided treatment interruptions with continuous ART (Strategies for Management of Antiretroviral Therapy [SMART] study) demonstrated an approximate 70% increase in CVD events in those taking treatment interruptions. Resolving the benefit of ART timing and its impact on CVD risk is a critical question for the field of clinical HIV care. If the benefits are significant, then prioritizing early diagnosis and linkage to ART might provide significant CVD health benefits. If the benefits are not significant, then the search for alternate interventions in addition to ART to mitigate CVD risk in this population will be crucial. This review aims to summarize the evidence about relationships between timing of ART initiation and CVD risk, using nadir CD4 count as a surrogate marker of duration of HIV infection, and with a particular focus on the impact of early ART on prevention of CVD events.

**THE SMART STUDY, TREATMENT INTERRUPTIONS, AND CARDIOVASCULAR DISEASE RISK**

Soon after it was discovered that combination ART profoundly improved survival for patients with AIDS [3, 4], it became evident that HIV-infected patients were at higher risk than the general population of non-AIDS-related conditions [5–8]. Cardiovascular disease, and particularly myocardial infarction and stroke, were among the greatest non-AIDS risks, and
ART rather than HIV infection was thought to be the primary culprit [5, 9, 10]. Concerns about avoiding the toxicity of chronic ART in part spurred a change in the US HIV treatment guidelines to downgrade recommendations to initiate ART for those with a CD4 of 200–350 from “recommended” to “optional” during the period 2001–2006 [11]; and a large randomized controlled trial was conducted to evaluate whether discontinuing ART decreased non-AIDS-related HIV complications. The SMART study randomized approximately 5000 patients infected with HIV on stable ART with a CD4 count above 350 to continuing ART, versus mandated treatment interruptions until CD4 counts dropped below 250, at which point ART was reinitiated [12].

Arguably the most informative result to come from the SMART study was not that treatment interruptions increased the risk of opportunistic infections or mortality, but that patients taking interruptions from ART had an approximately 70% increased risk of cardiovascular complications; moreover, major cardiovascular events occurred 5 times more often than opportunistic infections in those with treatment interruptions (Table 1). The SMART study suggested that, whereas specific ART drugs or drug classes might be associated with a relative CVD risk versus others [13, 14], CVD risk is largely mediated by the effects of untreated HIV infection.

Although the primary SMART study analysis did not differentiate between ART interruptions and timing of ART initiation, in a subsequent analysis, the investigators specifically considered a clinical benefit of earlier ART initiation. When limiting their analysis to the 488 study participants who were ART naive or off therapy for a minimum of 6 months before study enrollment, investigators found a 7 times increased hazard of a cardiovascular event or non-AIDS illness in those initiating therapy at <250 vs >350 cells/µL [15]. As the only study randomizing patients to early versus deferred ART initiation with measured CVD outcomes at the time, this study subanalysis offered the strongest clinical evidence for a preventive role for earlier ART initiation.

Since then, an elegant body of basic and translational research has provided a strong pathophysiologic rationale for a causative role for HIV infection on CVD risk [16]. A combination of immune activation due to HIV and coinfections [17–19], direct HIV infection of vasculature smooth muscle [20, 21], and profound and irreversible depletion of gut T-lymphocytes with resulting microbial translocation [22–24] are thought to combine to precipitate a chronic inflammatory state. Reactive T-lymphocytes and macrophages [25, 26] have been correlated with both CVD outcomes and all-cause mortality [27–30]. Indeed, recent data suggest that as mortality for HIV-infected individuals has decreased from AIDS-defining illnesses, CVD has become the second most common cause of death, after cancer, among those with an undetectable viral load [31]. However, although basic science supports the role of HIV-mediated inflammation as a causative agent in CVD risk, clinical data are crucial to translating this theory into improvements for patient care.

### ANTIRETROVIRAL THERAPY TIMING AND PRECLINICAL ATHEROSCLEROSIS

A host of nonrandomized studies have investigated the relationship between nadir CD4 count and risk of preclinical atherosclerosis, without convincing evidence for a relationship between disease stage at ART initiation and CVD risk (Table 2). It is notable that although multiple studies have reported a relationship between HIV infection itself and carotid intima media thickness (cIMT) [55], only 1 has demonstrated an inverse relationship between nadir CD4 count and cIMT (such that a lower nadir CD4 count is associated with a greater mean cIMT) [32]. In addition, although Hsue et al [43] reported a relationship between lower CD4 count and cIMT progression over time (Table 2), a large prospective study of over 1000 individuals infected with HIV has since reported a counterintuitive direct relationship (such that higher nadir CD4 count was associated with increased progression) [46]. These differential estimates might partially be explained by cohort characteristics. For example, patients in the Hsue et al [43] study had relatively low median nadir CD4 (approximately 200 vs 500 cells/µL), contained a higher proportion of males, and were more likely to be current smokers and have hypertension.

Although less commonly evaluated than cIMT, the presence of carotid plaques has been better associated with nadir CD4 count (Table 2). Investigators of the Multi-Centre AIDS Cohort Study and Women’s Interagency Health Study (MACS/WIHS) have reported greater carotid plaque volume with decreasing nadir CD4 count [33, 46]. This causal relationship is strengthened by the presence of a dose-response relationship correlating lower nadir CD4 count with increased prevalence and incidence of carotid plaque.

More recently, several studies have reported strong associations between HIV infection and presence of preclinical coronary artery disease and aortic wall inflammation (Table 2). The largest of these, also from the MACS/WIHS collaboration, reported a 20% decreased odds of coronary stenosis (>50%) for each increase in nadir CD4 count of 100 cells/µL [53]. However, similar to carotid atherosclerosis, the majority of similar studies have not found significant relationships between nadir CD4 count and preclinical disease (Table 2). It is notable that

---

**Table 1. Outcomes Reported in the SMART Study [12]**

| Outcome          | Relative Risk for Treatment Interruption | Total Events |
|------------------|----------------------------------------|--------------|
| Death            | 1.8 (1.2–2.9)                           | 85           |
| Serious OI       | 6.6 (1.5–29)                            | 15           |
| Major CV Event   | 1.7 (1.1–2.5)                           | 104          |

Abbreviations: CV, cardiovascular; OI, opportunistic infection; SMART, Strategies for Management of Antiretroviral Therapy.
### Table 2. Summary of Studies Reporting Relationships Between Nadir CD4 Count and Preclinical Atherosclerosis

| Study                                      | Year   | Study Design   | HIV-Infected Sample Size | Cohort Median Nadir CD4 Count | Relationship Between CD4 Nadir and Atherosclerosis Risk | Main Findings                                                                 |
|--------------------------------------------|--------|----------------|--------------------------|-------------------------------|--------------------------------------------------------|-------------------------------------------------------------------------------|
| **Current Carotid Intima Media Thickness** |        |                |                          |                               |                                                        |                                                                               |
| Jerico et al [32]                          | 2006   | Cross-sectional| 132                      | 250                           | Inverse                                                | Increased odds of cIMT >0.8 mm with a nadir CD4 count <200 vs ≥200 cells/µL (OR, 2.3, 95% CI, 1.4–5.9) |
| Kaplan et al [33]                          | 2008   | Cross-sectional| 1931                     | ~450*                         | None                                                   | No association between nadir CD4 count and mean cIMT in men (estimate not reported) |
| Ross et al [34]                            | 2009   | Cross-sectional| 73                       | 161 (0–866)                   | None                                                   | No association between nadir CD4 count and cIMT (β < 0.01, P = .88)            |
| van Vonderen et al [35]                    | 2009   | Cross-sectional| 77                       | ~184*                         | None                                                   | No association between cIMT and nadir CD4 count (estimate not reported)         |
| Merlini et al [36]                         | 2012   | Cross-sectional| 163                      | 210 (99–326)                  | None                                                   | No difference in nadir CD4 count between those with normal cIMT (≤1 cm), those with increased cIMT (1.0–1.5 cm), and those with carotid plaque (cIMT >1.5 cm), (P = .74) |
| Longenecker et al [37]                    | 2013   | Cross-sectional| 78                       | NR                            | None                                                   | No association between nadir CD4 count and mean cIMT (P = .80)                 |
| Desvarieux et al [38]                      | 2013   | Cross-sectional| 100                      | ~345*                         | None                                                   | No difference in adjusted mean cIMT between ART-naïve and on ART (β = .9)       |
| Ssinabulya et al [39]                      | 2014   | Cross-sectional| 245                      | 124 (42–195)                  | None                                                   | No difference in nadir CD4 count between those with elevated cIMT (≥0.78) and those with normal cIMT (P = .02) |
| Boyd et al [40]                            | 2014   | Cross-sectional| 47                       | ~222*                         | None                                                   | Nonsignificant association between cIMT and nadir CD4 count (β = −0.001, P = .9) |
| Siedner et al [41]                         | 2015   | Cross-sectional| 105                      | 122 (80–175)                  | Direct                                                 | Increase mean cIMT with each increase in nadir CD4 count of 50 cells/µL (0.014 mm, P = .02) |
| Pacheco et al [42]                         | 2015   | Cross-sectional| 591                      | 213 (90–314)                  | None                                                   | Mean nadir CD4 count 215 in lowest tertile of cIMT vs 178 in highest tertile of cIMT (P = .054) |
| **Progression of Carotid Intima Media Thickness** |        |                |                          |                               |                                                        |                                                                               |
| Hsue et al [43]                            | 2004   | Prospective cohort | 148                     | 106                           | Inverse                                                | Increased rate of progression of cIMT for participants with a nadir CD4 <200 (0.0043 mm/year, P = .08) |
| Currier et al [44]                         | 2007   | Prospective cohort | 134                     | NR (~35% with nadir CD4 <200) | Direct                                                 | Decreased odds of rapid progression of cIMT (defined as 1 SD, ie, 0.0122 mm/year) for participants with a nadir CD4 count <200 (ADOR, 0.10; P = .04) |
| Volpe et al [45]                           | 2013   | Prospective Cohort | 345                      | 161 (70–276)                  | Direct                                                 | Decreased rate of cIMT progression for each decrease in 100 cells/µL nadir CD4 count (~0.005 mm/year; SD, 0.002) |
| Hanna et al [46]                           | 2015   | Prospective Cohort | 1277                    | ~483*                         | None                                                   | No association between CD4 nadir and progression of cIMT thickness (IRR compared <200 cells vs >500 cells/µL 1.13, 95% CI, 1.6–2.29, P = .73). |
| Stein [47]                                 | 2015   | Randomized clinical trial | 328                     | 349 (203–455)                 | None                                                   | No association between pretreatment CD4% and cIMT progression (β = −0.07, P = .28) |
| **Current Carotid Artery Plaque**          |        |                |                          |                               |                                                        |                                                                               |
| Kaplan et al [33]                          | 2008   | Cross-sectional| 1931                     | ~450*                         | Inverse                                                | Increased adjusted risk of carotid plaque with lower nadir CD4 count (vs HIV-uninfected as reference group): CD4 nadir > 500: RR 0.88 (women), 1.24 (men), P > .18 CD4 nadir <200: RR 2.00 (women), 1.74 (men), P ≤ .05 |
| **Incident Carotid Plaque**                |        |                |                          |                               |                                                        |                                                                               |
| Hanna [46]                                 | 2015   | Prospective Cohort | 1277                    | ~483*                         | Inverse                                                | Increased adjusted risk of incident carotid plaque with lower nadir CD4 count (vs HIV-uninfected as reference group): CD4 nadir >500: RR 1.28, 0.85–1.94, P = .23 CD4 nadir 350–500: RR 1.65, 1.03–2.64, P = .039 CD4 nadir 200–350: RR 1.96, 1.20–3.11, P = .007 CD4 nadir <200: RR 2.57, 1.48–4.46, P < .001 |
| **Aortic Wall Inflammation (FDG PET)**     |        |                |                          |                               |                                                        |                                                                               |
| Subramanian et al [48]                     | 2012   | Cross-sectional| 27                       | 99 (60–250)                   | None                                                   | No correlation between nadir CD4 count and segment of plaque (P = .49), plaque volume (P = .66), or Agatston calcium score (P = .83) |
| **Preclinical Coronary Artery Disease**    |        |                |                          |                               |                                                        |                                                                               |
| Lo et al [49]                              | 2010   | Cross-sectional| 78                       | 169 (54–263)                  | None                                                   | No correlation between nadir CD4 count and aortic wall inflammation |
many of these studies are potentially unpowered to detect associations between nadir CD4 and CVD risk. Nonetheless, a meta-analysis of studies including data from approximately 1000 individuals infected with HIV found no significant association between nadir CD4 count and either noncalcified plaque (P = .45) or coronary artery stenosis (P = .87) [56].

**ANTIRETROVIRAL THERAPY TIMING AND CARDIOVASCULAR DISEASE OUTCOMES IN COHORT STUDIES**

Several large data sets in the United States, including the Veteran’s Aging Cohort Study (VACS), Partners Healthcare and the Kaiser Permanente Healthcare system, as well as large or national cohorts from France and Denmark, have enabled estimation of HIV-related CVD risk (Table 3). In general, these cohort studies increase the support for associations between nadir CD4 count and CVD risk. For example, in the Kaiser cohort, CVD incidence declined over calendar time (1999–2011) as population nadir CD4 increased. At the conclusion of their observation period (2010–2011), they found no difference in risk of myocardial infarction between HIV-infected and uninfected populations (relative risk [RR], 1.0; 95% CI, .7–1.4). The authors [67] point out that their data might be confounded by the fact that the proportion of patients receiving therapy for CVD-related conditions also increased during the period. However, if their estimates are unbiased, these data would support findings from the START study, which demonstrates normalization of CVD risk, compared with the general population, as nadir CD4 counts increased. A second study from the Kaiser investigators, which included more than 22,000 individuals infected with HIV, specifically assessed relationships between nadir CD4 and CVD risk and demonstrated a decreased risk of myocardial infarction with each 100 cell/µL increase in nadir CD4 count [61]. A case-control study from France noted a similar relationship [59]. Moreover, although the Partners cohort investigators, the VACS study investigators, and the HIV Outpatient Study investigators demonstrated relationships between recent CD4 count and risk of incidence myocardial infarction, they did not assess nadir CD4 count in their reports [28, 60], or they found no association between nadir CD4 and CVD events [58]. Finally, of 5 studies that have explored relationships between HIV disease stage and stroke risk, only 1 identified an inverse relationship between CD4 nadir and stroke risk (Table 3), reporting that a nadir CD4 count below 200 cells/µL more than doubled the risk of stroke [62].

**ANTIRETROVIRAL THERAPY TIMING AND CARDIOVASCULAR DISEASE OUTCOMES IN RANDOMIZED CLINICAL TRIALS: SMART VERSUS START**

Although the above body of evidence suggests a possible, if not inconsistent, role for early ART initiation in mitigating CVD risk, these data have a number of important limitations. First, many of the studies are limited to relatively small sample sizes, preventing the ability to detect small contributions of ART timing to CVD risk. Second, most cohort studies are homogeneous in important ways, including restricting to gender (eg, VACS and MACS cohorts), and, more importantly, to small distributions in nadir CD4 count, which limits the ability to compare those initiating early ART with those initiating late...
ART. Third, and most important, cohort studies are challenged by residual or unmeasured confounding, such that unaccounted factors associated with both nadir CD4 count and CVD risk (eg, access to high-quality primary care services) could alter estimates of the relationship between them. To overcome these limitations, randomization to early or deferred therapy is needed to better estimate relationships between timing of ART and CVD risk.

Both the SMART and START studies addressed this need through randomization of HIV-infected persons to ART or either ART discontinuation (SMART) or deferring ART initiation (START), respectively. As summarized above, the SMART study reported a 70% increased risk of cardiovascular complications for discontinuing therapy, whereas the START study found no increased risk of cardiovascular complications when initiating ART was deferred.

How can we explain the differences between these 2 studies? It is possible that treatment interruptions (as in SMART) have differential effects on CVD risk than delayed therapy among ART-naive individuals (as in START). However, as mentioned above, the SMART investigators identified similar relationships in a sub-study limited to those initiating ART [15]. There are other important differences between the 2 study populations, which theoretically could explain differences in relative rates of CVD events. For example, approximately 50% of patients in the SMART study were on a protease inhibitor, compared with only 20% of patients in the START study, and approximately 6% vs 4% were prescribed abacavir, respectively. Although the regimen imbalance might partially explain the relative increased overall risk of CVD events witnessed in the SMART study, it does not explain the difference in risk comparing those on ART with those who are not. In fact, the relationship observed was counterintuitive, because the regimens in use in the SMART study were more likely to be associated with metabolic abnormalities and would thus be predicted to have a relatively decreased effect on CVD prevention than the regimens used in the START study. Other key differences between study

### Table 3. Summary of Studies Reporting Relationships Between Nadir CD4 Count and Cardiovascular Disease Events

| Study | Year | Study Design | HIV-Infected Sample Size | Cohort Median Nadir CD4 Count | Relationship Between CD4 Nadir and Atherosclerosis Risk | Main Findings |
|---|---|---|---|---|---|---|
| Myocardial Infarction | | | | | | |
| Obel et al [57] | 2007 | Retrospective Cohort | 3953 | 182 (74–290) | None or inverse | Absolute increase in risk of myocardial infarction for those with nadir CD4 count ≤200 cells/µL (RR 2.28, 95% CI, 1.63–3.19) vs those with a nadir CD4 count >200 cells/µL (RR 1.80, 95% CI, 1.17–2.78). No interaction term reported. |
| Lichtenstein et al [58] | 2010 | Retrospective Cohort | 2005 | 197 | None | No association between nadir CD4 count and subsequent cardiovascular event (OR 1.34, 95% CI, 0.64–2.83 for nadir CD4 <350 vs >500) |
| Freiberg et al [60] | 2013 | Retrospective Cohort | 27 350 | 362 | None | No association between baseline CD4 (first record in veterans affairs system) and incident myocardial infarction (no estimate reported) |
| Silverberg et al [61] | 2015 | Retrospective Cohort | 22 081 | Not reported | Inverse | Decrease in risk of myocardial infarction with each 100-cell increase in nadir CD4 count (ARR 0.88, 95% CI 0.81–0.96). |
| Stroke | | | | | | |
| Rasmussen et al [62] | 2011 | Retrospective Cohort | 4495 | 292 | Inverse | Increase in risk of stroke among those not on ART with a nadir CD4 count ≤200 vs >200 cells/µL (ARR 2.28, 95% CI, 1.05–4.86). |
| Chow et al [63] | 2012 | Retrospective Cohort | 4308 | 271 | None | No association between nadir CD4 count and risk of stroke (0.97, 95% CI, 0.90–1.05 for each 50 cells/µL). |
| Vinikoor et al [64] | 2013 | Retrospective Cohort | 2515 | 235 (69–407) | None | No association between risk of ischemic stroke and nadir CD4 count ≤200 vs >200 cells/µL (RR 1.31, 95% CI, 0.76–2.26) for nadir CD4 count |
| Marcus et al [65] | 2014 | Retrospective Cohort | 24 788 | Not reported | None | Among the HIV+ group, no association between nadir CD4 count and risk of stroke (RR 0.80, 95% CI, 0.4–1.6 comparing nadir CD4<200 with ≥500). |
| Chow et al [66] | 2014 | Case Control | 60 | 73 | None | No association between nadir CD4 count and odds of ischemic stroke (OR 1.05, 95% CI, 0.81–1.36 per each 100 cells/µL) |

Abbreviations: ARR, adjusted relative risk; ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio; RR, relative risk.

* Median nadir CD4 count approximated from weighted average of subgroups.
groups include a higher median age in the SMART study (43 vs 36 years) and slightly higher rates of current smoking (40% vs 32%), but it is unlikely that these relatively modest differences would account for the approximately 7-fold increased risk of CVD events noted in the SMART study.

Another key difference between study groups was the nadir CD4 count. At enrollment, study participants in the START study had a median nadir CD4 count of 651 cells/µL and a known HIV duration of only 1 year. Moreover, mean CD4 count in the deferred therapy never dropped below 600 cells/µL. In contrast, the median nadir CD4 in the SMART study was 250 cells/µL, and over half of participants had over 6 years of HIV infection before enrollment. Those in the drug conservation group spent most of the observation time (73%) with detectable viral loads and with CD4 counts <500 cells/µL. As such, even the deferred therapy group in the START study can be considered to have significantly shorter duration of HIV viremia and duration of time with low CD4 counts compared with those in the SMART continued therapy arm.

An examination of these 2 studies in combination reveals a nonlinear relationship between nadir CD4 count and CVD risk (Table 4), and the results of this review challenges the implication supported by the START study, which, taken in isolation, suggests that early ART does not prevent CVD outcomes. Instead, early and continuous ART for those with advanced disease does appear to be protective against CVD events. However, for those starting ART relatively early (>500 cells/µL), CVD risk is not clearly reduced substantially by the timing of ART initiation. In other words, above some unclear threshold of immune depletion, earlier ART initiation seems to have a diminished role in preventing CVD. This realization should foster further consideration of non-ART interventions to decrease CVD risk among HIV-infected populations initiating therapy with preserved immune function [71, 72].

CONCLUSIONS

In summary, the published literature on the timing of ART initiation and CVD risk supports 3 primary conclusions. First, data from the SMART study, in combination with a handful of nonrandomized studies noting relationships between lower nadir CD4 and increased risk of preclinical or clinical CVD [32, 43, 53, 59, 61, 62], suggest that earlier initiation of ART has a protective effect against CVD events. The majority of these studies, including the SMART study, involved those with relatively low nadir CD4 counts (<250 cells/µL), which lends the strongest support for the benefit of ART among those with advanced disease. Notwithstanding recent recommendations to initiate ART independent of immune status, this implication remains of importance for much of the world’s HIV-infected population, because most patients continue to initiate ART well below recommended guidelines [68–70]. Second, a recent group of large cohort studies demonstrate associations between a low recent CD4 count (as opposed to nadir CD4 count) and/or current detectable HIV-1 viremia and clinical outcomes [28, 58, 60]. In combination with results of the SMART study, these data support a role for continuous ART among those who have initiated therapy, to prevent HIV-associated chronic inflammation and resulting CVD risk. Third, for patients starting ART above a CD4 count threshold of 500 cells/µL, the START study suggests that earlier ART initiation has marginal benefits in terms of mitigating CVD risk. This realization should foster further consideration of non-ART interventions to decrease CVD risk among HIV-infected populations initiating therapy with preserved immune function [71, 72].

Table 4. Nadir CD4 Count and Cardiovascular Disease Event Incidence in the SMART and START Studies

| Study Group                                      | Nadir CD4 | Cardiovascular Events | Event Rate |
|--------------------------------------------------|-----------|-----------------------|------------|
| SMART Treatment Interruption Arm                 | ~200      | 65                    | 1.8        |
| SMART Continued Therapy Arm                      | 250       | 39                    | 1.1        |
| START Deferred Initiation Arm                    | ~600      | 14                    | 0.20       |
| START Immediate Initiation Arm                   | 651       | 12                    | 0.17       |

Abbreviations: SMART, Strategies for Management of Antiretroviral Therapy; START, Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

References

1. The TEMPRANO ANRS 12136 Study Group, Daniel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373:808–22.
2. INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373:795–807.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725–33.
4. Palella FF Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853–60.
5. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723–35.
6. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179–93.
7. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292–8.
8. Currier JS, Taylor A, Boyd E, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506–12.
9. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479–86.
10. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747–8.
11. De Cock KM, El-Sadr WM. When to start ART in Africa–an urgent research priority. N Engl J Med 2013; 368:886–9.
12. El-Sadr WM, Landgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283–96.
13. Currier JS, Landgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008; 118:e29–35.
14. D:A:D Study GroupSabin CA, Worm SW, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients entered in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417–26.
15. Strategies for Management of Antiretroviral Therapy (SMART) Study Group; Emery S, Neuhaus JA, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133–44.
16. Hsue PY, Deeks SG, Hunt PW. Immuno logic basis of cardiovascular disease in HIV-infected adults. J Infect Dis 2012; 205:5375–82.
17. Sywester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202:673–85.
18. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126–33.
19. Wilton EM, Singh A, Hulsiek KH, et al. Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. J Infect Dis 2014; 210:1396–406.
20. Eugenin EA, Morgello S, Klotman ME, et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol 2008; 172:1100–11.
21. Dubé MP, Lishultz SE, Fichtenbaum CJ, et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008; 118:e36–40.
22. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of myocardial infarction. N Engl J Med 2002; 347:389–400.
23. De Cock KM, El-Sadr WM. When to start ART in Africa–an urgent research priority. N Engl J Med 2013; 368:886–9.
24. Kaplan RC, Kingsley LA, Gange SJ, et al. Low CD4+ T cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS 2008; 22:1615–24.
25. Ross AC, Ritz N, O’Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2009; 49:1119–27.
26. van Vonderen MG, Smullers YM, Stehouwer CD, et al. Carotid intima-media thickness and arterial stiffness in HIV-infected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009; 50:153–61.
27. Merliini E, Luzi K, Suardi E, et al. T-cell phenotypes, apoptosis and inflammation in HIV+ patients on virologically effective cART with early antiretroviralosis. PLoS One 2012; 7:e46073.
28. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747–8.
29. De Cock KM, El-Sadr WM. When to start ART in Africa–an urgent research priority. N Engl J Med 2013; 368:886–9.
30. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation in patients with attherosclerosis: role of combination antiretroviral therapy. Circulation 2008; 118:e29–35.
63. Chow FC, Regan S, Feske S, et al. Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US health care system. J Acquir Immune Defic Syndr 2012; 60:351–8.

64. Vinikoor MJ, Napravnik S, Floris-Moore M, et al. Incidence and clinical features of cerebrovascular disease among HIV-infected adults in the Southeastern United States. AIDS Res Hum Retroviruses 2013; 29: 1068–74.

65. Marcus JL, Leyden WA, Chao CR, et al. HIV infection and incidence of ischemic stroke. AIDS 2014; 28:1911–9.

66. Chow FC, Bacchetti P, Kim AS, et al. Effect of CD4+ cell count and viral suppression on risk of ischemic stroke in HIV infection. AIDS 2014; 28: 2573–7.

67. Klein DB, Leyden WA, Xu L, et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care. Clin Infect Dis 2015; 60:1278–80.

68. Hoffman S, Wu Y, Lahuerta M, et al. Advanced disease at enrollment in HIV care in four sub-Saharan African countries: change from 2006 to 2011 and multilevel predictors in 2011. AIDS 2014; 28:2429–38.

69. Lesko CR, Cole SR, Zinski A, et al. A systematic review and meta-regression of temporal trends in adult CD4(+) cell count at presentation to HIV care, 1992–2011. Clin Infect Dis 2013; 57:1027–37.

70. Siedner MJ, Ng CK, Bassett IV, et al. Trends in CD4 Count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: a meta-analysis. Clin Infect Dis 2015; 60:1120–7.

71. Lo J, Lu MT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2015; 2:e52–63.

72. Mitka M. Exploring statins to decrease HIV-related heart disease risk. JAMA 2015; 314:657–9.